These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29222940)

  • 1. An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.
    Roose E; Schelpe AS; Joly BS; Peetermans M; Verhamme P; Voorberg J; Greinacher A; Deckmyn H; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K
    J Thromb Haemost; 2018 Feb; 16(2):378-388. PubMed ID: 29222940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
    Underwood MI; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2024 Apr; 22(4):1069-1079. PubMed ID: 38160729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation.
    Bonnez Q; Dekimpe C; Bekaert T; Tellier E; Kaplanski G; Joly BS; Veyradier A; Coppo P; Lammertyn J; Tersteeg C; De Meyer SF; Vanhoorelbeke K
    J Thromb Haemost; 2024 Jul; 22(7):1936-1946. PubMed ID: 38554935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
    Zheng XL
    J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.
    Bettoni G; Palla R; Valsecchi C; Consonni D; Lotta LA; Trisolini SM; Mancini I; Musallam KM; Rosendaal FR; Peyvandi F
    J Thromb Haemost; 2012 Aug; 10(8):1556-65. PubMed ID: 22672482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Kremer Hovinga JA; Heeb SR; Skowronska M; Schaller M
    J Thromb Haemost; 2018 Apr; 16(4):618-629. PubMed ID: 29356300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
    Saha M; McDaniel JK; Zheng XL
    J Thromb Haemost; 2017 Oct; 15(10):1889-1900. PubMed ID: 28662310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.
    Scheiflinger F; Knöbl P; Trattner B; Plaimauer B; Mohr G; Dockal M; Dorner F; Rieger M
    Blood; 2003 Nov; 102(9):3241-3. PubMed ID: 12855569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
    Tersteeg C; Joly BS; Gils A; Lijnen R; Deckmyn H; Declerck PJ; Plaimauer B; Coppo P; Veyradier A; Maas C; De Meyer SF; Vanhoorelbeke K
    J Thromb Haemost; 2017 Dec; 15(12):2432-2442. PubMed ID: 28981198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura.
    De Waele L; Sakai K; Mancini I; Sinkovits G; Falter T; Inoue T; Agosti P; Rossmann H; Von Auer C; Tersteeg C; De Meyer SF; Joly BS; Veyradier A; Coppo P; Fijnheer R; Peyvandi F; Prohászka Z; Lämmle B; Vanhoorelbeke K
    J Thromb Haemost; 2024 Feb; 22(2):493-502. PubMed ID: 37866519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
    Shelat SG; Smith P; Ai J; Zheng XL
    J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.
    Feys HB; Liu F; Dong N; Pareyn I; Vauterin S; Vandeputte N; Noppe W; Ruan C; Deckmyn H; Vanhoorelbeke K
    J Thromb Haemost; 2006 May; 4(5):955-62. PubMed ID: 16689741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura.
    Mancini I; Ricaño-Ponce I; Pappalardo E; Cairo A; Gorski MM; Casoli G; Ferrari B; Alberti M; Mikovic D; Noris M; Wijmenga C; Peyvandi F;
    J Thromb Haemost; 2016 Dec; 14(12):2356-2367. PubMed ID: 27762046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
    Postmus T; Graça NAG; Ferreira de Santana J; Ercig B; Langerhorst P; Luken B; Joly BS; Vanhoorelbeke K; Veyradier A; Coppo P; Voorberg J
    J Thromb Haemost; 2023 Dec; 21(12):3402-3413. PubMed ID: 37633643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome.
    Yu F; Tan Y; Zhao MH
    Nephrol Dial Transplant; 2010 Jan; 25(1):145-52. PubMed ID: 19703836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
    Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
    Li A; Khalighi PR; Wu Q; Garcia DA
    J Thromb Haemost; 2018 Jan; 16(1):164-169. PubMed ID: 29064619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.